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For  cancers  lacking  standard  treatments,  comparing  new  agents  with  existing  treatments  is  problematic.
Here  we  discuss  the  study  design  from  the  AZA-001  trial,  which  compared  azacitidine  with  3  frequentlyeterogenous
tandard
ovel treatment
zacitidine
CR
used  conventional  care  regimens  (CCR)  for higher-risk  myelodysplastic  syndromes.  Before  randomiza-
tion, physicians  preselected  the most  appropriate  of  3  CCR  for  each  patient,  after  thorough  examination.
Patients  were  then  randomized  to  azacitidine  or CCR.  Patients  randomized  to CCR  received  their  prese-
lected treatment,  thus  including  patients  otherwise  excluded  as  poor  candidates  for  a  single  comparator.
This design  may  serve  as  a template  in  other  cancers  lacking  standard  therapy.. Introduction
Many cancers have accepted standard treatments that improve
emission rates and/or survival while others lack standard treat-
ent [1]. In such cancers, particularly those with low incidence,
esigning randomized trials to compare new drug treatments with
xisting therapies in representative patient populations is difﬁcult,
specially when limited to non-standard, suboptimal comparators.
The only curative approach in myelodysplastic syndromes
MDS) is allogeneic stem cell transplantation (Allo-SCT), for which
ew patients are eligible [2,3]. Until azacitidine’s activity in MDS
as demonstrated, particularly in higher-risk disease [4,5], com-
only used conventional care regimens (CCR) in patients ineligible
or Allo-SCT included acute myelogenous leukemia (AML) intensive
hemotherapy (IC) and low-dose cytarabine (LDAC). Their use was
argely dependent on patient age, performance status, and physi-
ian choice [6–13]. While prolonged overall survival (OS) is the
rimary treatment goal in higher-risk MDS  [14,15], neither LDAC
or IC consistently demonstrated OS beneﬁts over best support-
ve care (BSC) [6–8,10,11,13,16]. Therefore, many patients received
SC only.
Designing phase III randomized studies to compare effects
f azacitidine with existing treatments on OS prolongation was
hallenging. Comparing azacitidine with only one commonly
sed CCR would have limited patient enrollment to only good
andidates for that CCR, reducing trial result validity. We  planned
n international phase III trial to compare azacitidine with the 3
ost commonly used CCR for higher-risk MDS  at the time [17],
hus increasing the likelihood that enrolled patients would receive
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appropriate treatment, and maximizing the applicability of the
results in a diverse multinational patient population.
We describe the AZA-001 preselection trial design, its applica-
bility in higher-risk MDS, and other hematological disorders lacking
standard therapy.
2. Preselection study design
Preselection trial design (Fig. 1) requires site investigators to
assign patients at screening (before randomization) to one of two or
more unblinded protocol-speciﬁed CCR, based on patient medical
history, comorbidities, vital signs, laboratory results, disease sta-
tus, prognosis and demographics, together with national, regional,
and local treatment guidelines and patient preference. After pre-
selection is recorded, patients are randomized (1-to-1) to the
investigational drug arm or to the collective CCR arm, in which they
receive their preselected treatment (Fig. 1).
An important goal of investigator-preselection design is to
compare treatments between cohorts of patients with similar pre-
treatment disease and demographic characteristics. Investigator
preselection of the most appropriate protocol-speciﬁed treatment
before randomization increases the likelihood that patient prese-
lection cohorts have similar baseline characteristics for comparison
of the investigational drug cohort with the collective comparator
group and for the comparisons of the investigational drug with each
individual preselection subgroup (Fig. 1). Randomizing patients
after stratiﬁcation based on disease-risk category or other rele-
vant characteristics further insures balanced patient assignment.
Preselection design also gives site investigators treatment options,
minimizing patient assignment to inappropriate treatment and
enabling inclusion of patients who might otherwise opt out because
Open access under CC BY license.of the 50% chance of randomization to inappropriate treatment.
Additionally, preselection can facilitate adherence to treatment
guidelines based on patient demographics, performance status, and
disease characteristics.
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Table 1
Study treatment regimens used in the AZA-001 trial.
Study arm Treatment regimen
Azacitidine 75 mg/m2 per day subcutaneously for 7 days
every 28 days (delayed as needed to allow
blood-count recovery) for at least 6 cycles
Conventional care regimen
Best supportive care Includes blood product transfusions and
antibiotics with
granulocyte-colony-stimulating factor for
neutropenic infection
Low-dose cytarabine 20 mg/m2 per day subcutaneously for 14 days
every 28 days (delayed as needed to allow
blood-count recovery) for at least 4 cycles
Intensive chemotherapy Induction with cytarabine 100–200 mg/m2 per
day by continuous intravenous infusion for 7
days, plus 3 days of either intravenous
daunorubicin (45–60 mg/m2 per day),
idarubicin (9–12 mg/m2 per day), or
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. Experience with the preselection study design in
ZA-001
The international, multicenter, randomized, open-label AZA-
01 trial compared the treatment effect of azacitidine vs CCR (the
ollective CCR cohort) on OS prolongation in higher-risk MDS.
.1. Choice of comparator treatments
The 3 protocol-speciﬁed preselected CCR comparators for AZA-
01 – BSC, LDAC, and IC (Table 1) – were the most frequently used
herapies for higher-risk MDS  [6–13]. Although neither LDAC nor
C had shown convincing OS beneﬁts vs BSC [6,8,9,11–13,16], all
hree were considered feasible, reﬂecting consensus MDS  treat-
ent guidelines [18], and representing therapies used globally at
ZA-001 study sites [5–13,19,20].
.2. Study population
AZA-001 enrolled patients with higher-risk MDS, i.e., IPSS
ntermediate-2 or High risk disease and FAB-classiﬁed RAEB, RAEB-
, or CMML  (≥10% bone marrow blasts and white blood cell
ount < 13 × 109 L−1) [21,22]. Stratiﬁcation by IPSS risk and FAB
lassiﬁcation at randomization further minimized variability across
reatment arms.study design.
3.3. Statistical analyses
Approximately 354 patients with higher-risk MDS  were to be
randomized to receive azacitidine or CCR in a 1:1 ratio. Data from
several sources, including published CALGB 9221 data [5] for the
BSC-only group and similarly designed trials that used any of the 3
comparator options, were used for sample size calculation. Median
survival was  assumed to be 11 months for CCR and 18.3 months
for azacitidine. The number of expected deaths was 167, assuming
18 months accrual, at least 12 months of follow-up, and an overall
attrition rate of 30%. In addition, a misdiagnosis rate of 15% was
assumed for both groups. Using a log-rank analysis with a 2-sided
alpha-level of 0.05 provided 90% power to detect a 67% improve-
ment in OS in the azacitidine group (hazard ratio [HR] = 0.60).
Because of slow enrollment, actual enrollment and follow-up
required a 42-month study period that comprised 195 deaths, giv-
ing the trial 95% power to detect the HR speciﬁed in the trial design.
OS was  deﬁned as time from randomization to death from any
cause. The time-to-event analysis used Kaplan–Meier methodology
and stratiﬁed log-rank tests.
Comparisons within the 3 treatment preselection subgroups,
azacitidine vs BSC in patients preselected to BSC, azacitidine vs
LDAC in patients preselected to LDAC, and azacitidine vs IC in
patients preselected to IC (Fig. 2), were prospectively planned to
assess consistency of treatment effect across preselection sub-
groups and to determine whether azacitidine survival outcomes
were inﬂuenced by preselection.
4. Results
Patient demographic characteristics were well balanced
between the azacitidine and collective CCR arms and within the BSC
and LDAC preselection subgroups. Differences were observed in the
IC preselection subgroup, with patients being generally younger,
with healthier ECOG performance status, and with higher-risk dis-
ease [17]. Azacitidine signiﬁcantly prolonged OS in patients with
higher-risk MDS  vs collective CCR [17]. Comparison of OS prolon-
gation within the BSC and LDAC preselection subgroups (Fig. 2) was
signiﬁcant for azacitidine and consistent with the primary analysis.
In the IC preselection group, however, median OS of azacitidine-
treated patients was not statistically different from the median OS
of IC-treated patients [17].
5. Lessons learned from AZA-001 and their applicability toThe AZA-001 preselection study design allowed comparison of
azacitidine effect on OS with that of the 3 CCR overall and within
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he preselection subgroups. A study designed with 3 comparators
ut without treatment preselection before randomization would
ikely have not demonstrated the robust results of AZA-001, since
aseline characteristics of patients randomized to azacitidine or
CR would probably have been less balanced.
While AZA-001 preselection comparisons demonstrated the
uperiority of azacitidine for prolonging OS over BSC (9.6 months)
nd LDAC (9.2 months), no signiﬁcant difference between azaciti-
ine and IC was observed, despite a similar 9.3 month OS advantage
17], likely due to diminished statistical power from the small num-
er of IC-preselected patients (N = 42). Future studies might use
equired minimum sample sizes for each preselection subgroup
ased on statistical power considerations to control for treatments
ess frequently preselected. Alternatively, patient enrollment could
ontinue in a speciﬁc arm until sufﬁcient power was  achieved, and
hen discontinued. Enrollment would continue for the other prese-
ection treatments until sufﬁcient power was achieved. This design
ight also prolong trial duration.
As with all open-label studies, the AZA-001 trial was  subject
o potential biases associated with knowledge of treatment. For
xample, 4 patients (2.2%) randomized to azacitidine discontinued
efore treatment initiation compared with 14 patients (7.8%) ran-
omized to CCR. However, of the 14 patients randomized to CCR,
 had been preselected to BSC (2.9%), 5 to LDAC (10.2%), and 6 to
C (24.0%) [17]. Bias is difﬁcult to conﬁrm because of small patient
umbers, but investigator treatment preselection may  have inﬂu-
nced attrition. Thus, a trial designed to evaluate IC, for example,
ould have a selection bias for patients able and willing to toler-
te IC. Equally, a trial designed to evaluate active treatment versus
nly BSC could have a selection bias for patients and physicians
nwilling to accept the possibility of not receiving active therapy.
ven when multiple treatment options are available, as in AZA-001,
n investigator may  have declined to enroll a patient for whom
e or she believed a speciﬁc treatment was appropriate, because
he patient could have been randomized to study drug instead.
evertheless, for those patients who were enrolled, the preselec-
ion bias in AZA-001 reﬂects investigator judgment of a patient’s
est therapeutic option, thus giving the trial a “real world” aspect.
nother potential treatment bias could occur in international
tudies because treatment preferences can differ among countries.
n investigation into country-speciﬁc treatment preselections in
he AZA-001 study across eight European countries showed that
n pooled results from France and the UK, the most frequent pre-
election option was LDAC (74%), whereas in pooled results fromtion comparisons.
Germany, Italy, Spain, Sweden, Greece, and the Netherlands the
most frequent preselection option was  BSC (79%) [23]. Survival
analysis within each geographical subgroup showed an advantage
for the azacitidine group vs the CCR group similar to that observed
in the overall AZA-001 analysis. In future studies, stratifying within
countries may  minimize treatment preference biases.
At least one other study has utilized a similar design: the phase
III study of temsirolimus in relapsed mantle-cell lymphoma (r-MCL)
[24]. While numerous agents have some activity against r-MCL, no
clear consensus of standard therapy exists [25]. That study required
site investigators to nominate an intended single-agent treatment,
with patients subsequently randomized to the “physician-choice”
treatment or to one of two  temsirolimus dosing schedules. The
original protocol prespeciﬁed 6 allowed physician-choice therapies
but additional agents were allowed for small numbers of patients.
The primary study endpoint was progression-free survival (PFS),
with statistical powering for pair-wise comparisons of physician-
choice with each temsirolimus dose. The study was positive for
the higher-dose temsirolimus arm and not for the lower-dose arm.
Trial results led to FDA approval of temsirolimus for r-MCL. How-
ever, unlike the AZA-001 trial, the large number of physician-choice
treatments prevented direct comparison between temsirolimus
and each physician-choice therapy.
The preselection study design could also assess new drugs
in other malignancies for which no standard treatment exists,
e.g., newly diagnosed elderly AML. Currently, no consensus exists
regarding elderly patient “ﬁtness” for IC. Survival remains poor,
even with IC. Hypomethylating agents have demonstrated activ-
ity in elderly patients with AML  [26] and should now be compared
with CCR treatments: IC, LDAC, and BSC. Two  clinical trials could
be designed to study hypomethylating therapy, one enrolling
patients considered “ﬁt” for IC, another enrolling patients consid-
ered “unﬁt” for IC. Alternately, a single trial employing preselection
trial design could compare IC with a hypomethylating agent in
patients deemed “ﬁt” per investigator preselection to IC, and com-
pare the hypomethylating agent with LDAC in patients preselected
as “unﬁt” for IC. In the absence of consensus criteria for “ﬁtness,”
however, the validity of this approach might be questioned.
The preselection study design provides an effective model for
other randomized trials in diseases lacking standard therapy. Inves-
tigator preselection of comparator treatment enables inclusion of
a range of patients with varying disease states, allows compari-
son with current CCR, and provides direct comparison of treatment
effects across comparable patient subgroups. As more is learned
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bout molecular and cytogenetic heterogeneity of diseases such as
DS, it is clear that patients cannot be treated as a homogeneous
opulation for evaluation of emerging therapies. This might result
n smaller future trials, or larger trials using preselection method-
logies, allowing physicians to consider patient heterogeneity in
electing among treatment options to assess experimental drugs.
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